NeoImmuneTech, Inc.

62 articles with NeoImmuneTech, Inc.

• A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

  6/14/2022

  NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused therapeutics company, reported that Nature Communications (Impact Factor: 14.92) published the results of an in vivo study combining the long-acting human IL-7, NT-I7, with chimeric antigen receptor (CAR) T cells directed against CD19+ B cell lymphoma and acute myeloid leukemia.

• NeoImmuneTech to Present at Upcoming BIO International Convention

  6/13/2022

  NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang , Ph.D., MBA, will present a company update at the upcoming BIO International Convention, to be held June 13-16 in San Diego, CA.

• NeoImmuneTech's Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors

  6/6/2022

  NT-I7 plus pembrolizumab showed anti-tumor activity in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective.

• NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting

  4/27/2022

  NeoImmuneTech, Inc. today announced it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago, June 3-7, 2022.

• NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022

  4/13/2022

  Pre-clinical studies demonstrate NT-I7’s potential to enhance anti-tumor responses in combination with compounds targeting multiple biological pathways.

• 

  Money on the Move: March 9-15

  3/16/2022

  The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates. 

• NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting

  3/10/2022

  NeoImmuneTech, Inc. will be presented during poster sessions at the American Association for Cancer Research (AACR) annual meeting, to be held in New Orleans on April 8-13, 2022.

• NeoImmuneTech to Present at Upcoming Business Conferences

  2/9/2022

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY.

• NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

  2/7/2022

  NeoImmuneTech, Inc. today announced that the first patient has been dosed in the Phase 2a portion of a study evaluating NT-I7 (efineptakin alfa).

• Preclinical Data on NT-I7 Published in Clinical Cancer Research

  1/24/2022

  NeoImmuneTech, Inc. today announced the publication of preclinical data evaluating the company’s lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in mouse models of glioblastoma (GBM).

• NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference

  1/5/2022

  NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming Biotech Showcase at J.P. Morgan Healthcare Conference, to be held in a virtual format from January 10-12 and 17-19.

• NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

  11/22/2021

  NeoImmuneTech, Inc. today presented data from Phase 1 of an ongoing study at the Society for Neuro-Oncology (SNO) annual meeting.

• NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting

  11/16/2021

  NeoImmuneTech, Inc. today presented new data from two clinical trials evaluating the company’s lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in three posters at the Society for Immunotherapy of Cancer (SITC) annual meeting.

• NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  11/8/2021

  NeoImmuneTech, Inc. today announced that the first patient has been dosed in a Phase 2 study evaluating NT-I7

• NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma

  10/13/2021

  NeoImmuneTech, Inc. today announced that the first patient has been dosed in a Phase 1b study of its lead drug candidate, NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), following CAR-T cell therapy tisagenlecleucel (Kymriah®) in patients with relapsed/refractory (r/r) Large B-Cell Lymphoma (LBCL).

• NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting

  10/4/2021

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that new data from two clinical trials evaluating the company’s lead asset NT-I7 will be presented during poster sessions at the Society for Immunotherapy of Cancer annual meeting, to be held both in person in Washington, D.C. and on a virtual platform on November 10-14, 2021.

• NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting

  9/13/2021

  NeoImmuneTech, Inc. today announced that new data from a Phase 1/2 study evaluating the company’s lead asset NT-I7 (efineptakin alfa) will be presented during oral abstract sessions at the Society for Neuro-Oncology (SNO) annual meeting, to be held in Boston, Massachusetts on November 18-21, 2021.

• NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer

  8/25/2021

  NeoImmuneTech, Inc. today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).

• NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

  7/26/2021

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for a Phase 1 study evaluating the company’s lead asset, NT-I7, a novel long-acting human interleukin-7, for the treatment of Kaposi Sarcoma in patients with or without infection with HIV.

•  NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

  6/8/2021

  NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7.